1 / 32

Desflurane Toxicity

Desflurane Toxicity. 17 February 2004. Case. 27 year-old female, ASA II, presented for Right VATS/thoracotomy for excision of mediastinal extension of medullary thyroid cancer. PMHx: Medullary thyroid CA, GERD (no meds) Social: 1.5 pack-year smoking history.

sorcha
Download Presentation

Desflurane Toxicity

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Desflurane Toxicity 17 February 2004

  2. Case • 27 year-old female, ASA II, presented for Right VATS/thoracotomy for excision of mediastinal extension of medullary thyroid cancer. • PMHx: Medullary thyroid CA, GERD (no meds) • Social: 1.5 pack-year smoking history. • Meds: OCP, thyroid replacement in the past. • CT chest: Right paratracheal mass; no compression or deviation of trachea. • Wt: 79 kg Ht: 5’6” (BMI = 28)

  3. Case • PSH: • 8 July 2002: Right partial thyroidectomy • 15 July 2002: Completion thyroidectomy • 1 Oct 2003: Neck dissection

  4. Case • Anesthetic History: Elevated LFTs after 10/03 surgery; attributed by surgeons to “anesthesia.” • Comprehensive Metabolic Panel ordered post-op. • Unknown if occurred after other surgeries. • LFTs: • 10/1 at 0722 (pre-op): AST 19, ALT 30, TBil 0.5 • 10/1 at 2108 (post-op): AST 755, ALT 594, TBil 2.1 • 10/2: AST 156, ALT 332, TBil 0.5

  5. Differential Diagnosis • Pre-existing hepatic disease • Infection: Hepatitis A, B, C, D, E; CMV; EBV • Drugs: Acetaminophen, OCPs, alcohol, isoniazid, phenytoin, volatile anesthetics (esp. Halothane), mushrooms, etc. • Sepsis • TPN • Biliary obstruction • Intra-operative • Hypoxemia • Hepatic Ischemia: Increased venous pressure, decreased arterial pressure. • Drugs: Volatile anesthetics, hydralazine

  6. What did we do? (pre-op clinic) • Hepatitis Panel ordered (was not performed). • Related to OCPs? • Re-check LFT: • 11/2 (pre-op): AST 28, ALT 24, TBil 0.4

  7. What did we do? (Day of Surgery) • Review labs – back to normal. • Review record • Records unavailable at the time for previous surgeries. • 10/1/03- propofol, succinylcholine, sufentanyl, cefazolin, dexamethasone, ondansetron. Isoflurane/N2O/O2 for first 1.5 hours then Desflurane/N20/O2 for 6.75 hours. • Proceed with surgery using Desflurane (minimal, if any, hepatic biotransformation). • Discuss plan with patient

  8. 10/03 Anesthesia Record (p. 1)

  9. 10/03 Anesthesia Record (p. 2)

  10. 10/03 Anesthesia Record (p. 3)

  11. 11/3-Right VATS/Thoracotomy • Pre-Med: midazolam, vancomycin • Thoracic epidural: 0.2% ropivicaine • Induction: fentanyl, propofol, rocuronium, granisetron • DLT, A-line • Maintenance: desflurane/O2, fentanyl, rocuronium • Other: ondansetron, neostigmine/glycopyrolate

  12. 11/3 Anesthesia Record (p. 1) Epidural dosed.

  13. 11/3 Anesthesia Record (p. 2)

  14. 11/3 Anesthesia Record (p. 3)

  15. Post-op Labs • 11/3-AST 444, ALT 304, TBil 1.1 • 11/5-AST 59, ALT 112, TBil 0.5 • The patient denied any further testing at the time (hepatic US), saying “if anything is wrong with my liver, I don’t want to know. I’ve got too much going on with my thyroid already.” • Viral Hepatitis Panel—negative. • Discharged home on POD #3.

  16. Differential Diagnosis • Pre-existing hepatic disease • Infection: Hepatitis A, B, C, D, E; CMV; EBV • Drugs: Acetaminophen, OCPs, alcohol, isoniazid, phenytoin, volatile anesthetics (esp. Halothane), mushrooms, etc. • Sepsis • TPN • Biliary obstruction • Intra-operative • Hypoxemia • Hepatic Ischemia: Increased venous pressure, decreased arterial pressure. • Drugs: Volatile anesthetics, hydralazine

  17. Duplicated Drugs (10/1 & 11/3) • Propofol • Ondansetron • Desflurane

  18. Further Investigation • Previous Surgeries: • 8 July 2002: Right hemithyroidectomy • Midazolam, propofol, isoflurane/N2O/O2, sufentanyl. • 15 July 2002: Completion thyroidectomy • Midazolam, propofol, sevoflurane/N2O/O2, sufentanyl. **No LFTs checked after either surgery.

  19. Hepatic Effects of Volatile Anesthetics • Decreased portal hepatic blood flow (halothane most, isoflurane least). • Decreased hepatic arterial flow (except isoflurane increases). • Decreased hepatic metabolism.

  20. Halothane Hepatitis

  21. Halothane Hepatitis • Varies from asymptomatic LFT elevation to fulminant hepatic necrosis. • As high as 20% incidence in adults on 2nd exposure. Children seem to be more resistant. • Fatal hepatic necrosis estimated 1:35,000. • Risk factors: middle age, obesity, female sex, repeat exposure (esp. if within 28 days). • Diagnosis of exclusion. • Appears to be immune-modulated. • May have eosinophilia.

  22. Biotransformation of Volatile Agents Degree of volatile degradation is directly related to the potential for hepatic injury.

  23. *Isoflurane-one “isolated” chlorine atom; Desflurane-”devoid” of chlorine. * * *Substitution of fluorine for chlorine yields less biodegradation.

  24. Cases of Hepatotoxicity Reported as of 1995 • Desflurane: 1 • Isoflurane: 5 • Enflurane: 15 • Sevoflurane: few • Halothane: many

  25. Case Report of Desflurane Hepatic Injury—Only 1 in literature • Anesthesiology, Nov 1995 • 65 year-old female • Left hemithyroidectomy for adenoma • PSH: T&A 1935; BTL 1952; TAH 1969; Ex lap 1976; Cholecystectomy 1982. Halothane in 1976 & 1982, 45 minutes each. • PMHx: HTN, rare EtOH, no liver disease. • Allergy: iodine

  26. Case Report • SBP in mid-80’s just before incision, otherwise normal BP. Treated with ephedrine. • Maintenance with desflurane/N2O in 37-39% O2. • Minimal EBL. • Total anesthetic time of 90 minutes. • Discharged home.

  27. Case Report • POD #12: pruritis, malaise, nausea, polyarthralgias, rash on buttocks and thighs, dark urine noticed by patient. • POD #16: Jaundice, epigastric abdominal pain. Admitted to hospital. • LFTs elevated. • Viral hepatitis panel negative. • POD #22: Transferred to hepatology unit for potential liver transplantation. Repeat viral hepatis panel was negative; HSV and EBV tests revealed past infection. • POD #97: Symptom free with nearly normal liver function. No transplant was performed.

  28. Case Report • POD #48: ELISA for antibodies that react to liver-microsomes from halothane-treated rats versus untreated rats. • Antibody reactivity was higher against liver microsomes of halothane-treated rats than control rats, suggesting presence of antibodies in the patients serum formed by exposure to halothane.

  29. Trifluoroacetylated Antibodies (TFA) • Only patients with halothane hepatitis have antibodies that react with liver microsomal proteins that have been trifluoroacetylated (TFA) by the reactive trifluoroacetyl chloride halothane metabolite. • Similar immune process thought to occur with other volatile anesthetics but at lower incidence due to significantly less hepatic biodegradation.

  30. The Rest of the Story…. • Our patient will have specimen drawn on Feb 20th to be sent to John-Hopkins to have the ELISA for TFA performed (will be roughly POD #110).

  31. Conclusions • Of interest, our patient and the one patient reported were both having thyroid-related procedures. Could there be some immune mechanism induced by the thyroid cancer/adenoma? • Asymptomatic desflurane hepatitis may be more common than reported, we just don’t routinely check for it. • Desflurane still appears to be the most hepatic-friendly volatile agent from an immunology standpoint. Isoflurane may be best for the patient with known hepatic disease due to less net decrease in hepatic blood flow.

  32. Conclusions • Avoid hypoxia, hypotension. • DVT prophylaxis of choice (of course).

More Related